- Home
- MGN vs CLGN Comparison
MGN vs CLGN Comparison
Compare MGN & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGN | CLGN |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | Malaysia | Israel |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 5.2M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MGN | CLGN |
|---|---|---|
| Price | $2.13 | $3.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 123.4K | 50.6K |
| Earning Date | 11-29-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | $32.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.26 |
| 52 Week High | $5.18 | $4.78 |
Technical Indicators
Market Signals| Indicator | MGN | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 55.56 |
| Support Level | $0.11 | $0.34 |
| Resistance Level | $2.19 | $3.91 |
| Average True Range (ATR) | 0.36 | 0.39 |
| MACD | -0.26 | -0.09 |
| Stochastic Oscillator | 7.58 | 43.33 |
Price Performance
Historical ComparisonAbout MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.